Skip to main content
Log in

Overview of Personalized Medicine in GI Cancers

  • SSAT State-of-the-Art Conference
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Cancer biomarkers may be used for prevention (identification of patients at high risk for cancer), estimating prognosis and/or repsonse to conventional chemotherapies, or guide the use of specific targeted therapies. This overview provides examples in each category for gastrointestinal cancers and reviews current concepts in personalized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Srivastava A, McKinnon W, Wood ME. Risk of breast and ovarian cancer in women with strong family histories. Oncology (Williston Park) 2001;15:889-902; discussion 902, 905-7, 911-13.

    CAS  Google Scholar 

  2. Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol 2006;13:1296–321.

    Article  PubMed  Google Scholar 

  3. Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 2011;149:347–55.

    Article  PubMed  Google Scholar 

  4. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011;126:797–802.

    Article  PubMed  CAS  Google Scholar 

  5. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009;18 Suppl 3:S141–5.

    Article  PubMed  Google Scholar 

  6. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas AM, Van't Veer LJ, Tollenaar R. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17–24.

    Article  PubMed  Google Scholar 

  7. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937–44.

    Article  PubMed  Google Scholar 

  8. Salazar R, Marshall J, Stork-Sloots L, Simon I, Lutke Holzik M, Tabernero J, Van Der Hoeven JJ, Bibeau F, Rosenberg R. The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. J Clin Oncol 2010;28:(abstract, suppl. 15, aTPS199).

    Google Scholar 

  9. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104.

    Article  PubMed  CAS  Google Scholar 

  10. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–90.

    Article  PubMed  CAS  Google Scholar 

  11. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.

    Article  PubMed  CAS  Google Scholar 

  12. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.

    Article  PubMed  CAS  Google Scholar 

  13. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–8.

    Article  PubMed  CAS  Google Scholar 

  14. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.

    Article  PubMed  CAS  Google Scholar 

  15. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006;5:2.

    Article  PubMed  Google Scholar 

  16. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705–12.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Celia Chao.

Additional information

This paper was originally presented as part of the SSAT State-of-the-Art Conference, Personalized Medicine in Gastrointestinal Cancer: Potential Applications in Clinical Practice, at the SSAT 52nd Annual Meeting, May 2011, in Chicago, Illinois. The other articles presented in the conference were Riall TS, Introduction: Personalized Medicine in Gastrointestinal Cancer; Carethers JM, Proteomics, Genomics and Molecular Biology in the Personalized Treatment of Colorectal Cancer; Iacobuzio-Donahue CA, Personalized Medicine in Pancreatic Cancer: Prognosis and Potential Implications for Therapy; and DeMatteo RP, Personalized Therapy: Prognostic Factors in Gastrointestinal Stromal Tumor (GIST).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chao, C. Overview of Personalized Medicine in GI Cancers. J Gastrointest Surg 16, 1641–1644 (2012). https://doi.org/10.1007/s11605-012-1949-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-012-1949-8

Keywords

Navigation